Progress of tagraxofusp targeting CD123 in the treatment of blastic plasmacytoid dendritic cell neoplasm

VernacularTitle:靶向CD123药物Tagraxofusp治疗母细胞性浆细胞样树突状细胞肿瘤的研究进展
Author: Honggang CAO ¹ ; Ping CAO ; Jiuhu LIAN
Author Information

1. 甘肃省通渭县人民医院内科ICU，通渭　743300
Keywords: Blastocytic plasmacytoid dendritic cell neoplasm; CD123; Tagraxofusp; Targeted therapy
From: Journal of Leukemia & Lymphoma 2025;34(6):379-381
CountryChina
Language:Chinese
Abstract: Blastocytic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematological malignancy that can involve skin, bone marrow, lymph nodes, and other organs. The disease usually occurs in older men, and probably in children. There is no standard treatment regimen at present. Recently, tagraxofusp, a drug targeting CD123, was approved for the treatment of BPDCN abroad, which is the first drug approved for BPDCN, and also the first CD123-targeted drug in the field of oncology. This article reviews the recent research progress of tagraxofusp targeting CD123 in the treatment of BPDCN.